2024-518705-18-00招募中4 期
CROSS-OVER ANALYSIS OF THE CONTROL OF RISK FACTORS AND ANTIAGGREGATION WITH POLIPILL (POLICROSS TRIAL)
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 88
- 试验地点
- 1
- 主要终点
- Systolic blood pressure level. LDL cholesterol.
研究概览
简要总结
To analyze the level of systolic blood pressure and LDL-cholesterol in the same patient in 2 different periods: one under treatment of 3 months with the Trinomia® polypill and another of 3 months with the components separately.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Patients over 18 years of age. Patients with ischemic heart disease under treatment with the Trinomia® polypill in any of its presentations for secondary prevention and who can make the 6 visits necessary to complete the study. Patients who sign the Informed Consent.
排除标准
- •Patients who do not sign the informed consent. Patients with an inability to understand and comply with the protocol. Patients with contraindication to any component of the polypill. Patients who are already participating in another clinical trial. Patients with any condition that limits life expectancy to <1 year. Patients with programmed coronary revascularization. Patients with coronary stent implantation in the last 12 months. Patients treated with any antithrombotic drug in addition to acetylsalicylic acid, that is, low molecular weight heparin, P2Y12 receptor inhibitors, or oral anticoagulants.
结局指标
主要结局
Systolic blood pressure level. LDL cholesterol.
Systolic blood pressure level. LDL cholesterol.
次要结局
- Systolic blood pressure level. LDL cholesterol.
研究者
Armando Pérez de Prado
Scientific
Fundacion Epic
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effect of a Treatment With a Nutraceutical Combination on Sub-optimal LDL Cholesterol LevelsHypercholesterolemiaNCT03739242A. Menarini Industrie Farmaceutiche Riunite S.r.l.88
已完成
不适用
Coronary Heart Disease Risk Factors in Upwardly Mobile Blacks and WhitesCardiovascular DiseasesCoronary DiseaseHeart DiseasesObesityHypertensionNCT00005175National Heart, Lung, and Blood Institute (NHLBI)
招募中
不适用
Study of risk factors and end result of infection in seriously injured patientsCTRI/2022/10/046434niversity College of Medical Sciences and Guru Teg Bahadur Hospital
已完成
不适用
Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular EventsCardiovascular DisordersNCT01770210Elpen Pharmaceutical Co. Inc.670
已完成
3 期
Fixed dose combination of Azilsartan medoxomil and Chlorthalidone for tratment of hypertensionCTRI/2017/12/010961SYNOKEM Pharmaceuticals Limited306